Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Antibody-drug conjugates in gynecological cancers

Rebecca Porter, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights the emerging role of antibody-drug conjugates (ADCs) in gynecological cancers. ADCs have multiple targets in gynecological cancers, such as HER2, TROP2, and folate receptor-α (FRα). FRα-targeted ADCs are already approved for use in ovarian cancer and may be effective in endometrial cancers with over-expression of FRα. With immunotherapy being sequenced early in endometrial cancer treatment, ADCs are garnering more focus. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.